By Shannon Henson ( June 11, 2007, 12:00 AM EDT) -- Trouble continues to mount for the biotechnology company Dendreon Corp. since it announced in May that the U.S. Food and Drug Administration asked for more information regarding its advanced prostate cancer drug, Provenge. At least three securities lawsuits have been filed, two coming in the last week....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.